AR088793A1 - Compuestos y metodos para mejorar las respuestas inmunitarias innatas - Google Patents
Compuestos y metodos para mejorar las respuestas inmunitarias innatasInfo
- Publication number
- AR088793A1 AR088793A1 ARP120103945A ARP120103945A AR088793A1 AR 088793 A1 AR088793 A1 AR 088793A1 AR P120103945 A ARP120103945 A AR P120103945A AR P120103945 A ARP120103945 A AR P120103945A AR 088793 A1 AR088793 A1 AR 088793A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- halogen
- hydrogen
- nitrile
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 150000002825 nitriles Chemical class 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229940124530 sulfonamide Drugs 0.000 abstract 4
- 150000003456 sulfonamides Chemical class 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 3
- 150000003457 sulfones Chemical class 0.000 abstract 3
- 150000003462 sulfoxides Chemical class 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549784P | 2011-10-21 | 2011-10-21 | |
| US201261692431P | 2012-08-23 | 2012-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088793A1 true AR088793A1 (es) | 2014-07-10 |
Family
ID=48141628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103945A AR088793A1 (es) | 2011-10-21 | 2012-10-22 | Compuestos y metodos para mejorar las respuestas inmunitarias innatas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140249143A1 (enExample) |
| EP (1) | EP2768506A4 (enExample) |
| JP (1) | JP2014532626A (enExample) |
| KR (1) | KR20140094559A (enExample) |
| CN (1) | CN103957910A (enExample) |
| AR (1) | AR088793A1 (enExample) |
| AU (1) | AU2012325971B2 (enExample) |
| BR (1) | BR112014008727A2 (enExample) |
| CA (1) | CA2851801A1 (enExample) |
| CL (1) | CL2014001016A1 (enExample) |
| CO (1) | CO6910198A2 (enExample) |
| CR (1) | CR20140175A (enExample) |
| DO (1) | DOP2014000081A (enExample) |
| EA (1) | EA201490610A1 (enExample) |
| IL (1) | IL231894A0 (enExample) |
| MX (1) | MX2014004814A (enExample) |
| PE (1) | PE20141359A1 (enExample) |
| PH (1) | PH12014500865A1 (enExample) |
| SG (2) | SG11201400988SA (enExample) |
| TW (2) | TW201542567A (enExample) |
| UY (1) | UY34406A (enExample) |
| WO (1) | WO2013059559A2 (enExample) |
| ZA (1) | ZA201402392B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| JP2017531631A (ja) | 2014-09-29 | 2017-10-26 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 伝染性軟属腫ウイルスに対する抗ウイルス薬 |
| CN104529893B (zh) * | 2014-12-30 | 2016-08-24 | 中国科学技术大学 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| WO2018043747A1 (ja) * | 2016-09-05 | 2018-03-08 | 国立大学法人京都大学 | 抗ｂ型肝炎ウイルス剤 |
| EP3601286A4 (en) | 2017-03-28 | 2020-09-23 | Pimera, Inc. | NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR |
| CA3114551A1 (en) | 2018-10-23 | 2020-04-30 | Basf Se | Tricyclic pesticidal compounds |
| CN114732822B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| WO2021209265A1 (en) | 2020-04-14 | 2021-10-21 | Basf Se | Tricyclic pesticidal compounds |
| WO2022049521A1 (en) * | 2020-09-03 | 2022-03-10 | Glaxosmithkline Intellectual Property Development Limited | Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections |
| WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
| US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
| JP2024537824A (ja) | 2021-10-01 | 2024-10-16 | インサイト・コーポレイション | ピラゾロキノリンｋｒａｓ阻害剤 |
| MX2024004444A (es) | 2021-10-14 | 2024-05-08 | Incyte Corp | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). |
| WO2023244672A1 (en) | 2022-06-14 | 2023-12-21 | Assembly Biosciences, Inc. | 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections |
| AU2024252826A1 (en) * | 2023-04-14 | 2025-10-16 | HUMANWELL PHARMACEUTICAL US, Inc. | Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders |
| WO2025089372A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人理化学研究所 | イソインドリン誘導体 |
| WO2025128898A1 (en) | 2023-12-13 | 2025-06-19 | Assembly Biosciences, Inc. | Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL59104A (en) * | 1979-02-09 | 1984-02-29 | Roussel Uclaf | Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them |
| US4492697A (en) * | 1983-08-16 | 1985-01-08 | Ayerst, Mckenna & Harrison, Inc. | 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP2006503802A (ja) * | 2002-04-03 | 2006-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾ縮合化合物 |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JP5481671B2 (ja) * | 2009-03-31 | 2014-04-23 | ダイキン工業株式会社 | 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子 |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201002409D0 (en) * | 2010-02-12 | 2010-03-31 | Univ Nottingham | Methods |
-
2012
- 2012-10-19 JP JP2014537274A patent/JP2014532626A/ja active Pending
- 2012-10-19 US US14/353,067 patent/US20140249143A1/en not_active Abandoned
- 2012-10-19 BR BR112014008727A patent/BR112014008727A2/pt not_active IP Right Cessation
- 2012-10-19 CA CA2851801A patent/CA2851801A1/en not_active Abandoned
- 2012-10-19 WO PCT/US2012/060971 patent/WO2013059559A2/en not_active Ceased
- 2012-10-19 KR KR1020147013668A patent/KR20140094559A/ko not_active Withdrawn
- 2012-10-19 EP EP12840986.9A patent/EP2768506A4/en not_active Withdrawn
- 2012-10-19 EA EA201490610A patent/EA201490610A1/ru unknown
- 2012-10-19 SG SG11201400988SA patent/SG11201400988SA/en unknown
- 2012-10-19 PE PE2014000559A patent/PE20141359A1/es not_active Application Discontinuation
- 2012-10-19 AU AU2012325971A patent/AU2012325971B2/en not_active Ceased
- 2012-10-19 SG SG10201505664WA patent/SG10201505664WA/en unknown
- 2012-10-19 PH PH1/2014/500865A patent/PH12014500865A1/en unknown
- 2012-10-19 MX MX2014004814A patent/MX2014004814A/es unknown
- 2012-10-19 CN CN201280051347.8A patent/CN103957910A/zh active Pending
- 2012-10-22 AR ARP120103945A patent/AR088793A1/es unknown
- 2012-10-22 UY UY0001034406A patent/UY34406A/es not_active Application Discontinuation
- 2012-10-22 TW TW104126180A patent/TW201542567A/zh unknown
- 2012-10-22 TW TW101138997A patent/TW201333003A/zh unknown
-
2014
- 2014-03-18 CO CO14058151A patent/CO6910198A2/es unknown
- 2014-03-31 ZA ZA2014/02392A patent/ZA201402392B/en unknown
- 2014-04-03 IL IL231894A patent/IL231894A0/en unknown
- 2014-04-21 CL CL2014001016A patent/CL2014001016A1/es unknown
- 2014-04-21 CR CR20140175A patent/CR20140175A/es unknown
- 2014-04-21 DO DO2014000081A patent/DOP2014000081A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013059559A3 (en) | 2013-11-14 |
| CL2014001016A1 (es) | 2015-01-16 |
| UY34406A (es) | 2013-05-31 |
| SG11201400988SA (en) | 2014-07-30 |
| PE20141359A1 (es) | 2014-10-13 |
| BR112014008727A2 (pt) | 2017-04-25 |
| CN103957910A (zh) | 2014-07-30 |
| WO2013059559A2 (en) | 2013-04-25 |
| CA2851801A1 (en) | 2013-04-25 |
| ZA201402392B (en) | 2017-09-27 |
| KR20140094559A (ko) | 2014-07-30 |
| EP2768506A2 (en) | 2014-08-27 |
| CO6910198A2 (es) | 2014-03-31 |
| TW201333003A (zh) | 2013-08-16 |
| DOP2014000081A (es) | 2014-07-15 |
| SG10201505664WA (en) | 2015-09-29 |
| TW201542567A (zh) | 2015-11-16 |
| IL231894A0 (en) | 2014-05-28 |
| MX2014004814A (es) | 2014-05-27 |
| PH12014500865A1 (en) | 2014-05-26 |
| AU2012325971B2 (en) | 2016-03-31 |
| EP2768506A4 (en) | 2015-08-19 |
| JP2014532626A (ja) | 2014-12-08 |
| AU2012325971A1 (en) | 2014-04-17 |
| US20140249143A1 (en) | 2014-09-04 |
| CR20140175A (es) | 2014-06-03 |
| EA201490610A1 (ru) | 2014-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088793A1 (es) | Compuestos y metodos para mejorar las respuestas inmunitarias innatas | |
| AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
| AR092959A1 (es) | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR092522A1 (es) | Inhibidores de glucosilceramida sintasa | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR092348A1 (es) | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| AR104362A1 (es) | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR112290A1 (es) | Dinucleótidos cíclicos como agentes anticáncer | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR086817A1 (es) | Compuestos inhibidores de la fosfodiesterasa tipo 10a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |